This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding genetic markers for Wilms tumor may help identify patients who are at risk of relapse.
PRIMARY OBJECTIVES: I. To use a genome-wide association analysis to identify novel genetic variants that confer susceptibility to Wilms tumor. II. To improve our understanding of the genetic architecture and etiology of Wilms tumor. III. To facilitate the identification of genetic markers that are associated with an increased risk of developing of Wilms tumor and/or those at risk of aggressive disease, relapse, additional tumors and/or cancer in their offspring. OUTLINE: Samples are analyzed for single nucleotide polymorphism (SNP) profiling using real-time polymerase chain reaction (PCR) and multiplex ligation-dependent probe amplification (MLPA).
Study Type
OBSERVATIONAL
Enrollment
1
Correlative studies
Childrens Oncology Group
Philadelphia, Pennsylvania, United States
Frequencies between cases and controls at each SNP
Compared using the Cochran Armitage trend test (1-df). The data will be analyzed individually for the UK/US study populations and combined using a Mantel-Haenszel analysis adjusting for study group, and related methods which allow for different effects in each population (for confirmed loci, we will compare effects across populations).
Time frame: Baseline
Frequency of maternal and paternal allelic transmission for risk alleles
Compared using a chi-squared test.
Time frame: Baseline
Genetic variation on sub-phenotypes such as age at diagnosis, unilateral or bilateral disease, sex, and ethnicity
Time frame: Baseline
Interactions between genetic variation and treatment success or prognosis
Time frame: Baseline
Interactions between germline genetic variation and tumor phenotypes
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.